Coherus Oncology (CHRS) Non-Current Deffered Revenue (2013 - 2017)
Coherus Oncology (CHRS) reported Non-Current Deffered Revenue of $725000.0 for Q1 2017, down 97.8% on a YoY basis from $33.0 million in Q1 2016, and up 8.37% sequentially from $669000.0 in Q4 2016.
Coherus Oncology (CHRS) Non-Current Deffered Revenue (2013 - 2017) Analysis & Trends
Coherus Oncology (CHRS) has 5 years of Non-Current Deffered Revenue data on file, last reported at $725000.0 in Q1 2017.
- For the quarter ending Q1 2017, Non-Current Deffered Revenue fell 97.8% year-over-year to $725000.0; the trailing twelve-month figure through Mar 2017 stood at $725000.0 (down 97.8% YoY), and the FY2016 full-year result was $669000.0, down 98.52% from the prior year.
- Non-Current Deffered Revenue improved to $725000.0 in Q1 2017, from $669000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $45.3 million in Q4 2015 to a low of $595000.0 in Q3 2016.
- A 5-year average of $27.1 million and a median of $33.2 million in 2015 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue jumped 39.67% in 2014 and sank 98.52% in 2016, its largest moves.
- Tracing CHRS's Non-Current Deffered Revenue over 5 years: stood at $28.6 million in 2013, then surged by 39.67% to $39.9 million in 2014, then climbed by 13.63% to $45.3 million in 2015, then slumped by 98.52% to $669000.0 in 2016, then climbed by 8.37% to $725000.0 in 2017.
- Business Quant data shows CHRS's Non-Current Deffered Revenue at $725000.0 in Q1 2017, $669000.0 in Q4 2016, and $595000.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 725,000.00 |
| Dec 31, 2016 | 669,000.00 |
| Sep 30, 2016 | 595,000.00 |
| Jun 30, 2016 | 26.79 Mn |
| Mar 31, 2016 | 32.97 Mn |
| Dec 31, 2015 | 45.34 Mn |
| Sep 30, 2015 | 33.45 Mn |
| Jun 30, 2015 | 38.49 Mn |
| Mar 31, 2015 | 34.40 Mn |
| Dec 31, 2014 | 39.90 Mn |
| Sep 30, 2014 | 43.53 Mn |
| Dec 31, 2013 | 28.57 Mn |